Evidence map›Paper›PMID 39263917›Full record

ArticleMolecular oncology2025

ERK1/2 mitogen-activated protein kinase dimerization is essential for the regulation of cell motility.

Dalia de la Fuente-Vivas, Vincenzo Cappitelli, Rocío García-Gómez, Sara Valero-Díaz, Camilla Amato, Javier Rodriguéz, Santiago Duro-Sánchez, Alexander von Kriegsheim, Michael Grusch, José Lozano and 3 more

Abstract read
In one paragraph

Article in Molecular oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. ERK autoinhibition mechanism informs a drug combination strategy.Protein science : a publication of the Protein Society · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dalia de la Fuente-VivasInstituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC) - Universidad de Cantabria, Santander, Spain.
Vincenzo CappitelliInstituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC) - Universidad de Cantabria, Santander, Spain.
Rocío García-GómezInstituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC) - Universidad de Cantabria, Santander, Spain.
Sara Valero-DíazInstituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC) - Universidad de Cantabria, Santander, Spain.
Camilla AmatoInstituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC) - Universidad de Cantabria, Santander, Spain.
Javier RodriguézCancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, UK.
Santiago Duro-SánchezCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.ORCID https://orcid.org/0000-0002-3829-7562
Alexander von KriegsheimCancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, UK.
Michael GruschCenter for Cancer Research, Medical University of Vienna, Austria.ORCID https://orcid.org/0000-0001-5486-9340
José LozanoUniversidad de Málaga and Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina - IBIMA, Plataforma Bionand, Spain.
Joaquín ArribasCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.
Berta CasarInstituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC) - Universidad de Cantabria, Santander, Spain.ORCID https://orcid.org/0000-0002-3058-5631
Piero CrespoInstituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Consejo Superior de Investigaciones Científicas (CSIC) - Universidad de Cantabria, Santander, Spain.ORCID https://orcid.org/0000-0003-2825-7783

Funding

Breast Cancer Research Foundation BCRF-23-008Centro de Investigación Biomédica en Red de Cáncer CB16/12/00436Centro de Investigación Biomédica en Red de Cáncer JCSTF2105526Fundación Fero BFERO2021.03Instituto de Salud Carlos III PI22/00001Ministerio de Ciencia e Innovación PDC2022-133569-I00Ministerio de Ciencia e Innovación PID2020/112760RB-100Ministerio de Ciencia e Innovación PID2021-126288OB-I00Wellcome TrustWellcome Trust 208402/Z/17/Z
6 · The paper itself

Abstract

ERK1/2 mitogen-activated protein kinases (ERK) are key regulators of basic cellular processes, including proliferation, survival, and migration. Upon phosphorylation, ERK becomes activated and a portion of it dimerizes. The importance of ERK activation in specific cellular events is generally well documented, but the role played by dimerization is largely unknown. Here, we demonstrate that impeding ERK dimerization precludes cellular movement by interfering with the molecular machinery that executes the rearrangements of the actin cytoskeleton. We also show that a constitutively dimeric ERK mutant can drive cell motility per se, demonstrating that ERK dimerization is both necessary and sufficient for inducing cellular migration. Importantly, we unveil that the scaffold protein kinase suppressor of Ras 1 (KSR1) is a critical element for endowing external agonists, acting through tyrosine kinase receptors, with the capacity to induce ERK dimerization and, subsequently, to unleash cellular motion. In agreement, clinical data disclose that high KSR1 expression levels correlate with greater metastatic potential and adverse evolution of mammary tumors. Overall, our results portray both ERK dimerization and KSR1 as essential factors for the regulation of cell motility and mammary tumor dissemination.

Indexed as

Cell MovementMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Protein MultimerizationAnimalsBreast NeoplasmsCell Line, TumorFemaleHumansMAP Kinase Signaling SystemMicePhosphorylationProtein KinasesKSR-1 protein kinaseMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Protein Kinasescell motilityERKKSRMAP kinasesscaffold proteins

Identifiers

PMID39263917
PMCPMC11792999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.